The need for genetic studies of Indigenous Australians
Author: Gareth S Baynam
Published online: 19 March 2012
To the Editor: The continuing integration of genetic technologies into clinical medicine is providing opportunities for health care improvement. This has the potential to reduce health disparities between Indigenous and non-Indigenous Australians in several ways: improving our understanding of disease pathogenesis, obtaining a perspective from which to view environmental risks, improving prediction of disease risk, identifying new diagnostic techniques and drug targets, and making advances in pharmacogenomics.
Unfortunately, the dearth of genetic research involving Indigenous Australians may exclude them from such benefits of biomedical innovation.1 This is beginning to affect the clinical utility of genetic tests. For instance, in selected circumstances, single nucleotide polymorphism chromosomal microarrays (CMAs), which examine one’s chromosomal constitution at high resolution, are being employed to investigate a variety of phenotypes. To interpret the results of genetic investigations such as CMAs, it is a critical to understand the range of normal genetic variation, which is partly population specific. In addition, technologies such as next-generation sequencing, which can be used to analyse an individual’s exome or genome, will soon be used in clinical care. A survey conducted by Nature suggests that the current bias against studies of non-European people is likely to pervade these techniques.2 If so, a biased picture of which variants are important will emerge and, globally, genomic medicine will largely benefit a privileged (European) few.3 Notably, rare genetic variants (ie, those occurring in less than 5% of the world’s population) are disproportionately important in terms of complex disease risk and pharmacogenomics,4 and some are the cause of monogenic disease. Rare variations tend to be population specific. Accordingly, reference data from historically marginalised populations are needed to separate real from spurious findings.3 In addition, to help determine the significance of genotypic variation, there is a parallel need for accurate phenotypic information. Therefore, genetic studies will need to be coupled with detailed phenotyping, for which high-throughput phenomic assessments may be required.
Advances in genetic testing that will be used for clinical care therefore require engagement of Indigenous communities, so that normal genetic variation in these populations can be ascertained. To maximise benefit and minimise harm, this will need to be managed in an inclusive and culturally sensitive manner, with open discussion among all relevant parties.1 Failure to prioritise Indigenous genetic studies may perpetuate health inequity.

Competing interests
References
- Kowal E, Rouhani L, Anderson I. Genetic research in Aboriginal and Torres Strait Islander communities: beginning the conversation. Melbourne: The Lowitja Institute, 2011. 0_CHDGJIEH
- Genomes by the thousand. Nature 2010; 467: 1026-1027. 0_i1142869
- Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature 2011; 475: 163-165. 0_i1142871
- Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753. 0_i1142874
Costs of Delivering the Hep B PAST Model of Care in Remote Australia: A Retrospective Pre–Post Study
Hoa Nguyen, Anh Le Tuan Nguyen, Paula Binks, Melita McKinnon, Emily Vintour-Cesar, Karen Wills, Nicola Stephens, Benjamin Cowie, Joshua S. Davis, Yuejen Zhao, Peter Nihill, Julie A. Campbell, Andrew J. Palmer, Jane Davies, Barbara de Graaff
Epidemiology and Quality of Care for Aboriginal and Torres Strait Islander Peoples Treated by Emergency Medical Services for Stroke in Victoria, Australia: Retrospective Analysis of Linked Data
Candice Menezes, Ziad Nehme, Luke J. Burchill, Tegwyn McManamny, Angela Dos Santos, Michelle Crilly, Luke P. Dawson, Benjamin Clissold, David Anderson, Emily Nehme
Hepatitis C Among First Nations Australians: A Rethink Is Required to Meet the 2030 Elimination Target
James Ward, Emily Pegler, Kellie Stacy, Stephen Harfield
Sovereignty and Survival: Understanding Lung Cancer Outcomes for Aboriginal and Torres Strait Islander People in Australia, a Case–Control Study
Alice R. T. Bergin, Luc te Marvelde, Roger L. Milne, Benjamin J. Solomon, Kris Ivanova, Peter Savas, Stephen J. Luen, Jay Hamann, Andrea Casey, Nicole Watt, Sue M. Evans, Gail Garvey, Sherene Loi
Rethinking Rheumatic Fever Diagnosis: Progress, Pitfalls and the Path Towards a Definitive Test
Anna P. Ralph, Rachel Webb, Tom Parks, Nicole J. Moreland, Asha C. Bowen, Benjamin Jones, Emma Ndagire, Andrea Z. Beaton
Not Gone but Often Forgotten: Action Needed to Address Tuberculosis in Aboriginal and Torres Strait Islander Communities
Nikkita Joshua, Emma L. Smith, Eunice (Cheeky) Love, Christopher P. Lowbridge, Nicole Tukana, Amy Bowden, Megan A. Campbell, Dawn Casey, James Ward